prodige {BuyseTest} | R Documentation |
RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy.
Description
Simulated data inspired from the PRODIGE trial comparing the survival of patients with metastatic pancreatic cancer treated with FOLFIRINOX or gemcitabine .
-
id
: study participant. -
treatment
: treatment arm: FOLFIRINOX (T) or gemcitabine (C). -
OS
: time from inclusion (say diagnosis) to end of follow-up. -
statusOS
: event triggering the end of follow-up: death (1), drop-out (0). -
PFS
: time from inclusion (say diagnosis) to progression of the disease or end of follow-up. -
statusPFS
: progression (1) or end of follow-up (0). -
toxicity
: most serious side effect observed during the follow-up (1 mild, 6 severe). -
sex
: male (M) or female (F)
Usage
data(prodige, package = "BuyseTest")
Format
An object of class data.table
(inherits from data.frame
) with 823 rows and 8 columns.
Author(s)
Brice Ozenne
References
Conroy, Thierry, et al. "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer" New England Journal of Medicine (2011) 364(19):1817-25. doi: 10.1056/NEJMoa1011923.